Acute myocardial infarction (AMI) resulting from coronary plaque rupture or erosion, also known as type 1 AMI, remains a significant contributor to global cardiovascular morbidity and mortality [ , ]. The standard of care in AMI often involves urgent coronary revascularization by percutaneous coronary intervention (PCI) to promptly treat myocardial ischemia and restore coronary flow [ , ]. AMI patients are required to receive antithrombotic therapy throughout the acute and post-acute phases, which includes dual antiplatelet therapy (DAPT), to prevent recurrent coronary events [ ]. Although these pharmaco-invasive treatment strategies are well supported by randomized evidence from clinical trials and recommended by current guidelines for the majority of patients [ ], they may pose significant challenges for the particular subset of patients with hypercoagulable or bleeding disorders due to their unique risk profiles.